Pre-made Gevokizumab benchmark antibody ( Whole mAb, anti-IL1B therapeutic antibody, Anti-IL-1/IL1-BETA/IL1F2/IL1beta Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Gevokizumab biosimilar, Whole mAb, Anti-IL1B Antibody: Anti-IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta (IL-1 beta),[1] a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases.
| Products Name (INN Index) | Pre-Made Gevokizumab biosimilar, Whole mAb, Anti-IL1B Antibody: Anti-IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody |
|---|---|
| INN Name | Gevokizumab |
| Target | IL1B |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 4g6k:HL/4g6m:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | IRIS,National Eye Institute,North Shore-Long Island Jewish Health System,Novartis,Servier,University of Zurich,XOMA |
| Conditions Approved | NA |
| Conditions Active | Uveitis,Acne vulgaris,Acute coronary syndromes,Diabetic nephropathies,Giant cell arteritis,Labyrinthitis,Myositis,Osteoarthritis,Schnitzler syndrome,Scleritis,Colorectal cancer,Renal cell carcinoma |
| Conditions Discontinued | Rheumatoid arthritis,Cancer,Gout,Juvenile rheumatoid arthritis,Type 1 diabetes mellitus,Type 2 diabetes mellitus,Pyoderma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL1B |
| Package |
